Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.44 |
| ▸ | NPY2R | P49146 | 6/20 | 0.44 |
| ▸ | NPY4R | P50391 | 6/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.44 |
| ▸ | NPY1R | P25929 | 4/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29616793 | 0.86 | RAMP3 (0.49) | CXCR4OPRM1OPRK1 | |
| SCHEMBL30900793 | 0.85 | CALCRL (0.47) | CXCR4NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29906304 | 0.84 | OPRM1 (0.47) | CXCR4OPRM1OPRK1 | |
| SCHEMBL11168683 | 0.84 | RAMP3 (0.48) | OPRM1OPRK1NPY2RNPY4RNPY5R | |
| SCHEMBL9764520 | 0.84 | RAMP3 (0.48) | OPRM1OPRK1NPY2RNPY4RNPY5R | |
| SCHEMBL9764553 | 0.84 | RAMP3 (0.48) | OPRM1OPRK1NPY2RNPY4RNPY5R | |
| SCHEMBL11170810 | 0.84 | RAMP3 (0.48) | OPRM1OPRK1NPY2RNPY4RNPY5R | |
| SCHEMBL11170849 | 0.84 | RAMP3 (0.48) | OPRM1OPRK1NPY2RNPY4RNPY5R | |
| SCHEMBL11168724 | 0.84 | RAMP3 (0.48) | OPRM1OPRK1NPY2RNPY4RNPY5R | |
| SCHEMBL9763775 | 0.84 | RAMP3 (0.48) | OPRM1OPRK1NPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080292615-A1 | DIAGNOSIS AND TREATMENT OF DISEASE | MOLECULAR SKINCARE LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292615-A1 | DIAGNOSIS AND TREATMENT OF DISEASE | SERPINB1, EPCAM, DNASE1L3 | CXCR4 4050/4885OPRM1 3994/4885OPRK1 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.